犬扩张型心肌病(DCM)治疗药的全球市场:治疗方法，各给药途径，各流通管道，各地区，机会，预测，2018年～2032年

全球犬扩张型心肌病变药物市场规模预计将从 2024 年的 39.9 亿美元增长至 2032 年的 59 亿美元，在 2025-2032 年预测期内，复合年增长率为 5.01%。由于犬用药物的进步、宠物主人认知度的提高以及犬类扩张型心肌病变治疗需求的不断增长，全球犬扩张型心肌病变药物市场正在经历显着增长。

由于公众认知度的提高、诊断技术的进步以及犬类（尤其是大型犬和巨型犬）心臟病患病率的上升，该市场正在稳步增长。犬扩张型心肌病变 (DCM) 是一种严重的心肌疾病，主要选择的药物类别包括血管扩张剂（例如匹莫苯丹）、利尿剂和血管收缩酶 (ACE) 抑制剂，这些药物有助于改善心输出量和心臟功能，消除液体滞留，并减轻心臟负担。在市场发展和成长方面，犬扩张型心肌病变 (DCM) 的研发和产品开发正在进行中，许多新的治疗方案（包括基因疗法和更先进的製剂）正在被分析，以创造更好的、可能改善病情的疗法。全球犬扩张型心肌病变 (DCM) 药物市场也受到宠物人源化现象的影响。

此外，为了监管宠物人源化趋势，美国食品药物管理局 (FDA) 也透过批准新的治疗方案来提供支持。例如，2024 年 4 月，匹莫苯丹的首个仿製药——匹莫定咀嚼片 (Pimomedin Chewable Tablets) 获得 FDA 批准，用于治疗犬充血性心臟衰竭。这些药物可以增强心臟的肌肉收缩，并有助于扩张这些器官的血管。

本报告提供全球狗的扩大性心肌病(DCM)治疗药市场相关调查，提供市场概要，以及治疗方法，各给药途径，各流通管道，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 全球犬扩张型心肌病(DCM)治疗药市场预测，2018年～2032年

• 市场规模分析与预测
• 市场占有率分析与预测
  • 按治疗方法
    • 症状管理药
    • 缓解疾病药
    • 支持疗法剂
  • 给药途径
    • 口服
    • 注射
  • 各流通管道
    • 动物医院
    • 兽医诊所
    • 零售药局
    • 线上药局
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲
  • 各企业市场占有率分析(前五名公司以及其他- 各金额，2024年)
• 2024年的市场地图分析

第6章 北美的犬扩张型心肌病(DCM)治疗药市场预测，2018年～2032年

• 市场规模分析与预测
• 市场占有率分析与预测
• 各国市场评估
  • 美国
  • 加拿大
  • 墨西哥

第7章 欧洲的犬扩张型心肌病(DCM)治疗药市场预测，2018年～2032年

• 德国
• 法国
• 义大利
• 英国
• 俄罗斯
• 荷兰
• 西班牙
• 土耳其
• 波兰

第8章 亚太地区的犬扩张型心肌病(DCM)治疗药市场预测，2018年～2032年

• 印度
• 中国
• 日本
• 澳洲
• 越南
• 韩国
• 印尼
• 菲律宾

第9章 南美的犬扩张型心肌病(DCM)治疗药市场预测，2018年～2032年

• 巴西
• 阿根廷

第10章 中东·非洲的犬扩张型心肌病(DCM)治疗药市场预测，2018年～2032年

• 沙乌地阿拉伯
• 阿拉伯联合大公国
• 南非

第11章 需求供给分析

第12章 价值链分析

第13章 波特的五力分析

第14章 大环境分析

第15章 价格分析

第16章 市场动态

• 市场促进因素
• 市场课题

第17章 市场趋势与发展

第18章 法律规范

• 法规当局的认证
• 临床试验

第19章 专利的形势

第20章 案例研究

第21章 竞争情形

• 前五名市场领导的竞争矩阵
• 前五名参与企业的SWOT分析
• 前10名市场主要企业的形势
  • Boehringer Ingelheim International GmbH
  • Zoetis Inc.
  • Merck & Co., Inc.
  • Elanco Animal Health Incorporated
  • Vetoquinol group
  • Ceva Sante Animale
  • Bayer AG
  • Dechra Pharmaceuticals PLC
  • Orion Corporation
  • SAVA Vet

第22章 策略性建议

第23章 关于调查公司·免责声明

Global canine dilated cardiomyopathy drugs market is projected to witness a CAGR of 5.01% during the forecast period 2025-2032, growing from USD 3.99 billion in 2024 to USD 5.90 billion in 2032. The global canine dilated cardiomyopathy drugs market is experiencing significant growth due to advancements in canine drugs, increased awareness among pet owners, and growing demand for canine DCM treatment.

The market is witnessing a steady increase due to a rise in public awareness, along with advancements in diagnosis and an increasing prevalence of heart disease in dogs, particularly in large and giant breeds. Canine DCM is a severe heart muscle disease, and the main selected drug classes include vasodilators such as pimobendan, diuretics, and angiotension-converting enzyme (ACE) inhibitors to help improve cardiac output and function, relieve fluid retention, and reduce workload on the heart. With regards to the development and growth of the market, research and product development in Canine DCM is ongoing, and the market is analyzing many new treatment options, including genetic therapies and more advanced formulations to produce better and potentially disease-modifying therapies. The market for canine DCM drugs globally is also impacted by a larger phenomenon, which is pet humanization.

Additionally, to oversee the growing pet humanization trends Food and Drug Administration (FDA) also supports by giving approvals of new treatment plans. For instance, in April 2024, Pimomedin chewable tablets, the first generic pimobendane, received approval from the FDA for the management of congestive heart failure in dogs. These drugs help to strengthen the muscular contraction of the heart and widen the blood vessels in these organs.

Rising Prevalence of Canine DCM Drugs Drives Global Market Demand

Medical professionals in veterinary medicine face a rising need for specialized drugs to treat canine dilated cardiomyopathy because it represents a major veterinary medical problem. Dogs of large and giant breeds face the highest DCM risk because the disease primarily affects Dobermans, Great Danes, and Irish Wolfhounds. The condition's appearance in various dog breeds lately has led to inquiries about how diet choices, especially boutique and grain-free options that lack taurine, could be related to the problem. Modern diagnostic tools that include echocardiography and Holter monitoring provide better means to identify this condition. The general increase in pet ownership, along with growing public knowledge brought by social media platforms, together with obvious clinical symptoms of lethargy and coughing, and labored breathing, has led to an increasing number of reported cases of canine DCM.

For instance, in July 2024, Elanco Animal Health Incorporated announced a partnership with The Veterinary Cooperative (TVC) for an extensive portfolio of innovative products and practice resources and enhance the quality of care provided by TVC members.

The Rising Focus on Canine DCM Drug Innovation Drives Market Growth

The global market is undergoing substantial expansion owing to mounting pet populations and better awareness about dog cardiovascular conditions, along with veterinary medical advancements. Multiple pharmaceutical firms, along with research organizations, dedicate their resources to developing new medications that will enhance dog survival and quality of life by addressing DCM as a primary heart failure trigger among large canine breeds. The market surge stems from an increasing requirement for specialized pet care services and the establishment of strategic research partnerships between veterinary health organizations and expanding awareness about pets' benefits on human psychological health. Veterinary pharmaceutical and pet care industry stakeholders can find valuable information about emerging drug developments, together with market dynamics and economic effects of canine DCM treatments.

For instance, in February 2025, Mars Petcare's Waltham Petcare Science Institute launched a program to understand the human-animal bond shared benefits on National Love Your Pet Day. This study also aims to increase awareness of the role played by pets in maintaining owners' mental well-being.

Advances in Veterinary Medicine Drive the Canine Dilated Cardiomyopathy Drugs Market Demand

Progress in veterinary medicine has exponentially enhanced the ability to diagnose and treat canine DCM, increasing demand for canine drug products. Technology advancements such as high-resolution ECG and portable Holter monitor permit earlier diagnosis and continuous monitoring of the heart. Therapeutically, the development of novel drug formulation and delivery methods has improved efficacy and ease of use. Concerning ongoing treatment, telemedicine and digital monitoring systems have helped follow-up care more frequently and constantly than before, facilitating long-term disease management and reinforcing the critical role of veterinary medicine in DCM.

Additionally, to support the digitalization system in September 2023, iRhythm Technologies, Inc. introduced its next-generation Zio monitor and enhanced Zio long-term continuous monitoring (LTCM) service to enhance the cardiac monitoring experience for patients and healthcare providers, together with new service enhancements. It is based on an AI algorithm that supports the capture and analysis of ECG data.

Therapeutic Drugs Hold the Largest Canine Dilated Cardiomyopathy Drugs Market Share

Therapeutic drugs hold the largest market share as they are necessary to manage life-threatening diseases by controlling symptoms and disease progression. These include positive inotropes such as pimobendane, ACE inhibitors, beta-blockers and diuretics, which form the basis of any treatment protocol to improve cardiac function, decrease fluid retention, and ultimately improve the quality of life of affected dogs. With the increasing diagnostic rate of DCM being partly due to increased awareness and the ability to perform advanced veterinary diagnostics, the need for well-established drug therapies is likely to increase.

For instance, in May 2024, UpCard-CA1 drugs, the first torsemide oral solution for dogs, received approval from the FDA, which is a concurrent therapy to be used for pulmonary edema in dogs with congestive heart failure secondary to myxomatous mitral valve disease (MMVD).

North America Dominates the Global Canine DCM Drugs Market Size

The North America region holds the primary position in the canine dilated cardiomyopathy (DCM) drugs market, owing to elevated veterinary care expenditures, established medical facilities, and innovative pharmaceutical research. The rising trend of humanizing pets leads to an increase in market demand owing as numerous pet owners select specialized treatments for conditions such as DCM. Through advanced veterinary systems, which include specialized hospitals and board-certified cardiologists, the diagnosis and treatment of veterinary patients are supported. Animal health companies that lead the industry dedicate significant resources to research and development to develop innovative cardiac medications. The combined effects of these elements result in North America becoming the main market for DCM drug sales worldwide.

Additionally, to oversee the growing pet humanization trends in this region organization also provides pet health insurance across Canada and the United States. For instance, in April 2025, the National American Pet Health Insurance Association, Inc. (NAPHIA) released its survey result, which shows that about 7.03 million pets were insured in North America at the end of 2024.

Impact of U.S. Tariffs on Global Canine Dilated Cardiomyopathy Drugs Market

US tariffs have the potential to affect the global canine dilated cardiomyopathy (DCM) drugs market by raising costs and impacting different supply chains. Most veterinary pharmaceuticals (as well as DCM drugs) are produced using foreign active pharmaceutical ingredients (APIs) and resources. Tariffs imposed on imported APIs increase the production costs of the manufacturer, that usually passed on to the veterinary clinics and pet owners, resulting in higher prices for the DCM treatment drugs. Some pet owners may delay treatment or not have the ability to afford the treatment, which could negatively impact animal welfare and demand for the products. Tariffs may also force companies to search for alternative suppliers, which may take time to locate or produce a delay or disruption in the product to the marketplace due to disrupted supply chains.

Key Players Landscape and Outlook

Continuous innovation and constant change promote the global canine dilated cardiomyopathy drugs market. Companies are investing in research and development to target new canine heart diseases with more effective treatments. Companies intend to improve drug product development, treatment options, and the safety and efficacy of medication used in the treatment of canine DCM. Many drug companies are strategically aligning their product development and market strategies with greater demand around a companion animal emphasis of pet health and wellness. The presence of an additional online veterinary pharmacy and tele-veterinary service will also change how treatment is accessed in the current market and beyond.

For instance, in November 2024, Boehringer Ingelheim International GmbH introduced VETMEDIN Solution approved by Food and Drugs Administration (FDA) to manage congestive heart failure in dogs to increase the survival time and provide quality of life in dogs who are affected by MMVD (myxomatous mitral valve disease) or DCM (dilated cardiomyopathy).

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Therapeutic Approach
    • 5.2.1.1. Symptom Management Drugs
      • 5.2.1.1.1. Diuretics
      • 5.2.1.1.2. Vasodilators
    • 5.2.1.2. Disease-Modifying Drugs
      • 5.2.1.2.1. ACE Inhibitors
      • 5.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
      • 5.2.1.2.3. Pimobendan
    • 5.2.1.3. Supportive Care Agents
      • 5.2.1.3.1. Anti-Arrhythmics
      • 5.2.1.3.2. Cardiac Glycosides
  • 5.2.2. By Route of Administration
    • 5.2.2.1. Oral
    • 5.2.2.2. Injectable
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Veterinary Hospitals
    • 5.2.3.2. Veterinary Clinics
    • 5.2.3.3. Retail Pharmacies
    • 5.2.3.4. Online Pharmacies
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Therapeutic Approach
  • 5.3.2. By Route of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Therapeutic Approach
    • 6.2.1.1. Symptom Management Drugs
      • 6.2.1.1.1. Diuretics
      • 6.2.1.1.2. Vasodilators
    • 6.2.1.2. Disease-Modifying Drugs
      • 6.2.1.2.1. ACE Inhibitors
      • 6.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
      • 6.2.1.2.3. Pimobendan
    • 6.2.1.3. Supportive Care Agents
      • 6.2.1.3.1. Anti-Arrhythmics
      • 6.2.1.3.2. Cardiac Glycosides
  • 6.2.2. By Route of Administration
    • 6.2.2.1. Oral
    • 6.2.2.2. Injectable
  • 6.2.3. By Distribution Channel
    • 6.2.3.1. Veterinary Hospitals
    • 6.2.3.2. Veterinary Clinics
    • 6.2.3.3. Retail Pharmacies
    • 6.2.3.4. Online Pharmacies
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Therapeutic Approach
        • 6.3.1.2.1.1. Symptom Management Drugs
        • 6.3.1.2.1.1.1. Diuretics
        • 6.3.1.2.1.1.2. Vasodilators
        • 6.3.1.2.1.2. Disease-Modifying Drugs
        • 6.3.1.2.1.2.1. ACE Inhibitors
        • 6.3.1.2.1.2.2. Angiotensin II Receptor Blockers (ARBs)
        • 6.3.1.2.1.2.3. Pimobendan
        • 6.3.1.2.1.3. Supportive Care Agents
        • 6.3.1.2.1.3.1. Anti-Arrhythmics
        • 6.3.1.2.1.3.2. Cardiac Glycosides
      • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.2.1. Oral
        • 6.3.1.2.2.2. Injectable
      • 6.3.1.2.3. By Distribution Channel
        • 6.3.1.2.3.1. Veterinary Hospitals
        • 6.3.1.2.3.2. Veterinary Clinics
        • 6.3.1.2.3.3. Retail Pharmacies
        • 6.3.1.2.3.4. Online Pharmacies
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Canine Dilated Cardiomyopathy (DCM) Drugs Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework

• 18.1. Regulatory Approvals
• 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Boehringer Ingelheim International GmbH
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. Zoetis Inc.
  • 21.3.3. Merck & Co., Inc.
  • 21.3.4. Elanco Animal Health Incorporated
  • 21.3.5. Vetoquinol group
  • 21.3.6. Ceva Sante Animale
  • 21.3.7. Bayer AG
  • 21.3.8. Dechra Pharmaceuticals PLC
  • 21.3.9. Orion Corporation
  • 21.3.10. SAVA Vet

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 3. Global Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 4. Global Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 5. Global Canine Dilated Cardiomyopathy Drugs Market Share (%), By Region, 2018-2032F
• Figure 6. North America Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 7. North America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 8. North America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 9. North America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 10. North America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
• Figure 11. United States Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 12. United States Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 13. United States Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 14. United States Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Canada Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Canada Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 17. Canada Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 18. Canada Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 19. Mexico Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 20. Mexico Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 21. Mexico Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 22. Mexico Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 23. Europe Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Europe Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 25. Europe Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 26. Europe Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 27. Europe Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
• Figure 28. Germany Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Germany Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 30. Germany Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 31. Germany Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 32. France Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 33. France Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 34. France Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 35. France Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 36. Italy Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 37. Italy Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 38. Italy Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 39. Italy Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. United Kingdom Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 41. United Kingdom Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 42. United Kingdom Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 43. United Kingdom Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 44. Russia Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Russia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 46. Russia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 47. Russia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 48. Netherlands Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 49. Netherlands Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 50. Netherlands Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 51. Netherlands Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. Spain Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 53. Spain Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 54. Spain Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 55. Spain Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Turkey Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Turkey Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 58. Turkey Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 59. Turkey Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 60. Poland Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 61. Poland Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 62. Poland Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 63. Poland Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 64. South America Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 65. South America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 66. South America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 67. South America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 68. South America Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
• Figure 69. Brazil Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Brazil Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 71. Brazil Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 72. Brazil Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 73. Argentina Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 74. Argentina Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 75. Argentina Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 76. Argentina Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 77. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 78. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 79. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 80. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Asia-Pacific Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
• Figure 82. India Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 83. India Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 84. India Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 85. India Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 86. China Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 87. China Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 88. China Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 89. China Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 90. Japan Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Japan Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 92. Japan Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 93. Japan Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 94. Australia Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 95. Australia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 96. Australia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 97. Australia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 98. Vietnam Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 99. Vietnam Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 100. Vietnam Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 101. Vietnam Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 102. South Korea Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 103. South Korea Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 104. South Korea Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 105. South Korea Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 106. Indonesia Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 107. Indonesia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 108. Indonesia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 109. Indonesia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 110. Philippines Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 111. Philippines Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 112. Philippines Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 113. Philippines Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 114. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 115. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 116. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 117. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 118. Middle East & Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Country, 2018-2032F
• Figure 119. Saudi Arabia Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 120. Saudi Arabia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 121. Saudi Arabia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 122. Saudi Arabia Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 123. UAE Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 124. UAE Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 125. UAE Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 126. UAE Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 127. South Africa Canine Dilated Cardiomyopathy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 128. South Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Therapeutic Approach, 2018-2032F
• Figure 129. South Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 130. South Africa Canine Dilated Cardiomyopathy Drugs Market Share (%), By Distribution Channel, 2018-2032F
• Figure 131. By Therapeutic Approach Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 132. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024